SoGAT 14-06-2006 June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,

Slides:

Advertisements

Similar presentations

Chagas Tests: Development and Standardization

Advertisements

Marta José, Instituto Grifols S.A., Barcelona, SPAIN

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

The Sense of Sensitivity I Dr. Matthias Gessner Plasma Control Europe/Plasma Analytics Baxter AG, Vienna.

Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA

Evaluation of Rapid Screening Methods for Emergency Blood Collections CPT Robert.

F. Kourgia, M. Vini, E. Zervou

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.

HIV Testing CDC power point edited by M. Myers

Testing Source Plasma for Hepatitis B Virus by Nucleic Acid Testing Blood Products Advisory Committee Meeting Blood Products Advisory Committee Meeting.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.

E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.

Limitations of HBsAg testing in the screening of blood donors Wolfram H. Gerlich Institute of Medical Virology University Giessen, Germany SoGAT XVI Langen.

Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.

BioLife Plasma Services Experience with HBV NAT Testing

And the order changeth …. Evolving protocols for TTI testing

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.

Michael Chudy, Paul-Ehrlich-Institut SoGAT XVIII, Bethesda MD

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.

Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.

Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.

Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.

NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.

SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,

1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.

E A 1 Supplemental Testing for HIV-1 and HCV Blood Products Advisory Committee Meeting September 18, 2003 Susan L. Stramer, Ph.D. National Testing.

SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.

Active B19 virions production in hepatoblastoma and hepatocarcinoma cell lines: amplification and genomic stability. Op de beeck A. 1, Draps M.-L. 1, Baurin.

Anti-B19 screening for safe cellular blood products for at–risk patients SoGAT XVIII, USA, May 24-25th, 2005 Harry Bos on behalf of Project Group Parvo.

Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.

Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.

Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.

A multi-centre NAT evaluation study of run and trend control samples Harry van Drimmelen 1, Joe O’Donnellan 2, Rene Bax 1, Henrik Ullum 3 and the Danish.

Natural history of HBV infection (adapted from Torbenson Lancet 2003) Chronic infection Healthy carriage Recovery occult DNA Anti-HBe Anti-HBc Immune response.

NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.

SoGAT 2005 Donor screening for parvovirus B19 antibodies: Reducing or eliminating the risk of transmission SoGAT 2005 Gordon Elliott Biotrin 93 The Rise.

Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.

PROPOSED CANDIDATE MATERIAL FOR A WHO PANEL FOR SEROLOGICAL REFERENCE RESULTS OF THE FEASIBILITY STUDIES WITH SERA FROM TC I REGION RESULTS OF THE FEASIBILITY.

Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000

Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.

DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories.

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

DRK-Blutspendedienst West  nPrecipitation steps (PEG), centrifugation and careful resuspension of the invisible pelleted viral particles precede efficient.

E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.

February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.

SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.

Informational Presentation: WHO Biological Standards Summary of January 29-30, 2007 WHO Meeting with WHO Collaborating Centres for Biological Standards.

Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.

Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.

BioPlex 2200 HIV Ag-Ab Assay

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.

GRIFOLS PLASMA: genotype 2 vB19 sample

Tom Øystein Jonassen, Mona Holberg-Petersen, Einar S. Berg

Longitudinal Quality Assurance of HIV Nucleic Acid Testing in Blood Screening D Jardine, S Best, EM Dax (National Serology Reference Laboratory, Australia)

HBV/G Infection of an Apheresis Donor

Viral Safety of Blood Products in Taiwan

SoGAT Meeting, Berne, 14 June 2006 M. Nübling (PEI, Germany)

Comparison of a commercial and ‘in house’ assay for B19 DNA

SoGAT meeting XXI May (2009), Brussels, Belgium

Presentation transcript:

SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#, Theo Cuijpers#, Marco Koppelman#, Mirjam de Waal#, Arlinke Bokhorst*, Noor Holsboer*. # Sanquin Diagnostic Services, Amsterdam; * BIS- Foundation, Leiden, The Netherlands

Tests on blood borne infections for tissue release Bone, ossicle Anti-HIV-1/2/antigen (Combo) HIV p24 antigen discont. HIV-1 DNA Anti-HTLV-I/II HBsAg Anti-HBc total Anti-HCV HCV/HIV-RNA test pools IgG anti-CMV TPPA Tissue: cornea, skin, cardiac valve Anti-HIV-1/2/antigen (Combo) HIV p24 antigen discont. Anti-HTLV-I/II HBsAg Anti-HBc total (pos. anti-HBs) Anti-HCV HCV/HIV-RNA test pools TPPA

Testing tissue donors in test pools of 4 for HCV/HIV-RNA NAT NucliSens extractor (BioMerieux), AmpliScreen HCV test vs 2.0., Ampliscreen HIV test vs 1.5. System for blood screening of Sanquin. Tissues: testing in test pools of 4 samples. Input per donor sample 50 ul EDTA plasma. Filling up to 1 ml with 0.8 ml negative human plasma. Sensitivity per ml donor plasma * : HCV-RNA 95 % hit rate 840 geq/ml ( % CI) 165 IU/ml HIV-RNA 95 % hit rate 1280 geq/ml ( % CI) 806 IU/ml *Calculated on dilution factor based on analytical validation Jongerius et al. Transfusion 42, (2002) and Koppelman et al. 89, (2005).

Validation of testing tissue donors in test pools of 4 for HCV-RNA NAT. Robustness on frozen samples, retrospectively analyzed. 320 non-selected samples from tissue donors. -Acceptable level of invalid results: 0.6 % of the test pools. Responsible individual sample can be traced. -Robust test, 95 % of the pools have a saturated signal for the IC (OD>2.5). Sensitivity. Spiking of representative test pools with 300 geq (58.8 IU) HCV-RNA -Level of 6000 geq/ml (1175 IU/ml) for the individual sample is guaranteed. Nearly all spiked samples saturated wild-type signals.

Validation of testing tissue donors in test pools of 4 for HIV-RNA NAT (1). Robustness on frozen samples, retrospectively analyzed: 166 non-selected samples from tissue donors; 36 test pools. Samples frozen as test pool of four. 13/36 (36 %) test pools significantly reduced IC signal (OD<1.5).

Validation of testing tissue donors in test pools of 4 for HIV-RNA NAT (2). Sensitivity. Spiking of 27 test pools with 280 geq (176 IU) HIV-RNA. Samples frozen as test pools of four. 5 pools with significantly reduced WT signal (OD<1.5): one invalid, one false negative and 3 IC signal 0.2 and 1.5.

On-line analysis of test pools HIV-/HCV-RNA (1) Sampling and centrifugation (asap) in Plasma Preparation Tubes (B&D). Shipment and storage at 4-8 o C. HCV-RNA period ( / ) 202 test pools, 808 donors. HIV-RNA period ( / ) 166 test pools, 664 donors. No reactive donors for HIV-RNA and HCV-RNA. No confirmed serological pos. donors for HIV and HCV. 4/808 (0.5%) donors invalid result HCV-RNA 3/664 (0.5%) donors invalid result HIV-RNA 3/664 (0.5%) donors invalid as result of HCV/HCV NAT testing.

On-line analysis of test pools HIV-/HCV-RNA (2) HCV-RNAHIV-RNA Result test pool Result breakdown Result test pool Result donor Positive WT> n.a. Invalid IC<1.5 84*4* 7&7& 3#3# Negative WT<0.2 IC> n.a.159n.a. &2 test pools no break down. * 28 donors negative # 17 donors negative

Analysis of test pools HIV-/HCV-RNA; Robustness HCV IC<1.5 4 % IC≥1.5 and <2.5 3 % IC≥ % Total202 HIV IC<1.5 4 % IC≥1.5 and <2.5 8 % IC≥ % Total166 HCV HIV

Conclusions Spiking experiments on test pools of 4 with inhibiting substances: Increase of Cut-off value IC signal invalid/negative OD=1.5 Testing in pools of 4 with 50 ul of plasma per tissue donor for HCV-/HIV-RNA yields an acceptable level of invalid results (0.5 %) for the individual donor. The number of false positive results for test pools is low (0.5 % for HCV-RNA, 0 % for HIV-RNA). The NucliSens extractor AmpliScreen HCV/HIV assay performed on test pools of 4 tissue donor is a robust test, 93 % of the pools have a saturated signal for the HCV-IC; 88 % for HIV-RNA. The HCV-/HIV-RNA assay in test pools is applied for routine tissue release since February 2006.